Inhibition of phosphodiesterase 5 restores endothelial function in renovascular hypertension
Authors:
- Ananda T DiasADAnanda T Dias
- Amanda S CintraACAmanda S Cintra
- Jéssica C FrossardJFJéssica C Frossard
- Zaira PalominoZPZaira Palomino
- Dulce E CasariniDCDulce E Casarini
- Isabele Bs GomesIGIsabele Bs Gomes
- Camille M BalariniCBCamille M Balarini
- Agata L GavaAGAgata L Gava
- Bianca P CampagnaroBCBianca P Campagnaro
- Thiago MC PereiraThiago MC Pereira
- Silvana S MeyrellesSMSilvana S Meyrelles
- Elisardo C VasquezEVElisardo C Vasquez
Open Access
- 16 September 2014
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 12 (1) , 1-14
Abstract
The clipping of an artery supplying one of the two kidneys (2K1C) activates the renin-angiotensin (Ang) system (RAS), resulting in hypertension and endothelial dysfunction. Recently, we demonstrated the intrarenal beneficial effects of sildenafil on the high levels of Ang II and reactive oxygen species (ROS) and on high blood pressure (BP) in 2K1C mice. Thus, in the present study, we tested the hypothesis that sildenafil improves endothelial function in hypertensive 2K1C mice by improving the NO/ROS balance. 2K1C hypertension was induced in C57BL/6 mice. Two weeks later, they were treated with sildenafil (40 mg/kg/day, via oral) or vehicle for 2 weeks and compared with sham mice. At the end of the treatment, the levels of plasma and intrarenal Ang peptides were measured. Endothelial function and ROS production were assessed in mesenteric arterial bed (MAB). The 2K1C mice exhibited normal plasma levels of Ang I, II and 1–7, whereas the intrarenal Ang I and II were increased (~35% and ~140%) compared with the Sham mice. Sildenafil normalized the intrarenal Ang I and II and increased the plasma (~45%) and intrarenal (+15%) Ang 1–7. The 2K1C mice exhibited endothelial dysfunction, primarily due to increased ROS and decreased NO productions by endothelial cells, which were ameliorated by treatment with sildenafil. These data suggest that the effects of sildenafil on endothelial dysfunction in 2K1C mice may be due to interaction with RAS and restoring NO/ROS balance in the endothelial cells from MAB. Thus, sildenafil is a promising candidate drug for the treatment of hypertension accompanied by endothelial dysfunction and kidney disease.Keywords
This publication has 68 references indexed in Scilit:
- Sildenafil ameliorates oxidative stress and DNA damage in the stenotic kidneys in mice with renovascular hypertensionJournal of Translational Medicine, 2014
- Sildenafil ameliorates biomarkers of genotoxicity in an experimental model of spontaneous atherosclerosisLipids in Health and Disease, 2013
- Atorvastatin and sildenafil lower blood pressure and improve endothelial dysfunction, but only atorvastatin increases vascular stores of nitric oxide in hypertensionRedox Biology, 2013
- Endothelial Dysfunction in the Apolipoprotein E-deficient Mouse: insights into the influence of diet, gender and agingLipids in Health and Disease, 2011
- Common Secondary Causes of Resistant Hypertension and Rational for TreatmentInternational Journal of Hypertension, 2011
- Administration of a low dose of sildenafil for 1 week decreases intrahepatic resistance in rats with biliary cirrhosis: the role of NO bioavailabilityClinical Science, 2010
- Angiotensin II Infusion Alters Vascular Function in Mouse Resistance Vessels: Roles of O–·2 and EndotheliumJournal of Vascular Research, 2005
- Evaluation of Vascular Function in Apolipoprotein E Knockout Mice With Angiotensin-Dependent Renovascular HypertensionHypertension, 2005
- Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanismsEuropean Journal of Pharmacology, 2004
- Unraveling the Mystery of Goldblatt HypertensionPhysiology, 1998